Positive News SentimentPositive NewsNASDAQ:MREO Mereo BioPharma Group (MREO) Stock Price, News & Analysis $0.29 -0.01 (-4.08%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.52%) As of 10/30/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Mereo BioPharma Group Stock (NASDAQ:MREO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mereo BioPharma Group alerts:Sign Up Key Stats Today's Range$0.28▼$0.3250-Day Range$0.24▼$0.4052-Week Range$0.20▼$2.37Volume543,621 shsAverage Volume845,644 shsMarket Capitalization$46.23 millionP/E RatioN/ADividend YieldN/APrice Target$1.67Consensus RatingHold Company Overview Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and oncology. The company’s research programs are intended to address conditions with significant unmet medical needs, using biologic and small-molecule drug candidates. Mereo’s lead program is setrusumab, an investigational monoclonal antibody designed to inhibit sclerostin and stimulate bone formation. The therapy is being developed for osteogenesis imperfecta, a rare genetic disorder characterized by fragile bones, through a collaboration with Ultragenyx Pharmaceutical. Mereo has also developed investigational treatments targeting other rare-disease and cancer indications, including programs involving neutrophil elastase and immune-checkpoint pathways. Founded in 2015, Mereo BioPharma is headquartered in London, United Kingdom, and has conducted research, development and clinical activities across the United States and Europe. As a clinical-stage company, its products remain under investigation and are subject to regulatory review and the results of ongoing clinical trials.AI Generated. May Contain Errors. Read More Mereo BioPharma Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreMREO MarketRank™: 3.34393663983 of 5 starsMereo BioPharma Group scored higher than 67% of companies evaluated by MarketBeat, and ranked 283rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingMereo BioPharma Group has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialMereo BioPharma Group has a consensus price target of $1.67, representing about 475.7% upside from its current price of $0.29.Amount of Analyst CoverageMereo BioPharma Group has only been the subject of 4 research reports in the past 90 days.Read more about Mereo BioPharma Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mereo BioPharma Group are expected to grow in the coming year, from ($0.04) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mereo BioPharma Group is -7.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mereo BioPharma Group is -7.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mereo BioPharma Group's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.16% of the float of Mereo BioPharma Group has been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 2.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mereo BioPharma Group has recently increased by 20.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentMereo BioPharma Group has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mereo BioPharma Group this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows1 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.Percentage Held by Insiders6.50% of the stock of Mereo BioPharma Group is held by insiders.Percentage Held by Institutions62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mereo BioPharma Group's insider trading history. Receive MREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MREO Stock News HeadlinesHead-To-Head Review: Incyte (NASDAQ:INCY) and Mereo BioPharma Group (NASDAQ:MREO)October 20, 2026 | americanbankingnews.comMereo BioPharma Group plc(NasdaqCM:MREO) dropped from S&P Global BMI IndexSeptember 22, 2026 | marketscreener.comMWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.October 31 at 1:00 AM | Brownstone Research (Ad)Mereo BioPharma Group PLC ADRSeptember 6, 2026 | barrons.comMereo BioPharma Group plc: Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung ...August 11, 2026 | finanznachrichten.deMereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate HighlightsAugust 11, 2026 | markets.businessinsider.comMereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)August 11, 2026 | markets.businessinsider.comSentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)August 11, 2026 | prnewswire.comSee More Headlines MREO Stock Analysis - Frequently Asked Questions How have MREO shares performed this year? Mereo BioPharma Group's stock was trading at $0.4167 at the beginning of the year. Since then, MREO shares have decreased by 30.5% and is now trading at $0.2895. How were Mereo BioPharma Group's earnings last quarter? Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) issued its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). When did Mereo BioPharma Group IPO? Mereo BioPharma Group (MREO) raised $50 million in an initial public offering on Wednesday, April 24th 2019. The company issued 2,838,021 shares at $17.62 per share. How do I buy shares of Mereo BioPharma Group? Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mereo BioPharma Group investors own include Palantir Technologies (PLTR), NVIDIA (NVDA), Tesla (TSLA), SoFi Technologies (SOFI), Advanced Micro Devices (AMD), FuelCell Energy (FCEL) and Geron (GERN). Company Calendar Last Earnings8/12/2026Today10/31/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, MREO's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MREO CIK1719714 Webwww.mereobiopharma.com Phone44-33-3023-7300FaxN/AEmployees39Year Founded2015Price Target and Rating Average Price Target for Mereo BioPharma Group$1.67 High Price Target$3.00 Low Price Target$1.00 Potential Upside/Downside+475.7%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.88 million Net MarginsN/A Pretax Margin-7,142.00% Return on Equity-74.82% Return on Assets-64.28% Debt Debt-to-Equity RatioN/A Current Ratio5.88 Quick Ratio5.88 Sales & Book Value Annual Sales$500 thousand Price / Sales92.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.11Miscellaneous Outstanding Shares159,690,000Free Float149,311,000Market Cap$46.23 million OptionableOptionable Beta0.20 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:MREO) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MREO Stock Alerts